-1752956837198.webp&w=3840&q=75)
2025 NOSCM | Metastatic Colorectal Cancer: Novel Advances
Overview
Dr. Axel Grothey highlighted metastatic colorectal cancer advances. Kairos 6 showed a 17% 5-year DFS gain from perioperative chemo. CheckMate 8HW and ANCHOR trials showed 34% reduced progression with nivolumab+ipilimumab and encorafenib+cetuximab. Future focus: targeting RAS mutations with pan-RAS inhibitors.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Axel Grothey, MD
Date of Release
July 20th, 2025
-1755988787553.webp&w=3840&q=75)
-1755988610269.webp&w=3840&q=75)